Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
By contrast, calcitriol users had substantially more cardiometabolic conditions, including chronic kidney disease, diabetes, hypertension, ischaemic heart disease and congestive heart failure, and higher comorbidity and frailty burden (p < 0.001 for all).
Source: Medicine Choice Among Early Initiators. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Patterns of Osteoporosis Treatment Initiation Following Low‐Trauma Fracture: A Population‐Based Retrospective Cohort Study in New South Wales, Australia, Using Linked Administrative Health Data
Source: Article title.
There were no missing data for analysed variables, as all participants were Medicare‐enrolled and records were linked using unique AIHW and CHeReL identifiers.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Patterns of Osteoporosis Treatment Initiation Following Low‐Trauma Fracture: A Population‐Based Retrospective Cohort Study in New South Wales, Australia, Using Linked Administrative Health Data
Cohort study · The Medical Journal of Australia · 2026
Original publication title
Patterns of Osteoporosis Treatment Initiation Following Low‐Trauma Fracture: A Population‐Based Retrospective Cohort Study in New South Wales, Australia, Using Linked Administrative Health Data
© 2026 The Author(s). Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To characterise osteoporosis medicine prescribing patterns following low‐trauma fractures and identify predictors of early treatment initiation.
Source: ObjectivesAbstract: Study Type
Retrospective population‐based cohort study.
Source: Study TypeAbstract: Setting
New South Wales, Australia, using statewide linked administrative health data.
Source: SettingAbstract: Participants
Adults aged ≥ 50 years with an incident low‐trauma fracture between January 2011 and June 2019.
Source: ParticipantsAbstract: Main Outcome Measures
Primary outcomes were osteoporosis treatment prescribing patterns and timing of initiation after incident fracture over 3 years, categorised as early (within 12 months), late (within 1 to 3 years) or no initiation. Secondary analyses examined predictors of time to treatment initiation within 12 months using Fine: Gray competing‐risk regression.
Source: Main Outcome MeasuresAbstract: Results
Among 132,268 individuals with incident fractures, 63.7% (84,222) were female. Overall, 29,802 (22.5%) initiated osteoporosis medicine, whereas 102,466 (77.5%) remained untreated. Among females (mean [standard deviation] age, 77.7 [10.1] years), 20.1% initiated therapy within 12 months, 7.0% within 1 to 3 years, and 72.9% remained untreated. Among males (mean [standard deviation] age, 77.2 [10.0] years), the corresponding proportions were 10.8%, 3.7% and 85.6%. After accounting for the competing risk of death, treatment initiation was more likely with non‐distal fractures, older age, polypharmacy, prior steroid use, prior dual‐energy x‐ray absorptiometry and later fracture year, and less likely with greater comorbidity, rural or regional residence and prior hospitalisation for falls.
The strongest associations were for hip or vertebral fracture (subdistribution hazard ratio range, 1.90 to 3.03) and high comorbidity burden (subdistribution hazard ratio range, 0.72 to 0.75). Almost one in four late initiators had a refracture before starting treatment. Denosumab rapidly replaced oral bisphosphonates as the dominant therapy over time.
Source: ResultsAbstract: Conclusion
More than three‐quarters of individuals remain untreated after fracture, highlighting persistent and substantial gaps in secondary fracture prevention. Treatment initiation is strongly associated with fracture site and multimorbidity burden, and initiation rates are lower in males. Increasing reliance on denosumab underscores the need for careful long‐term treatment planning and strategies.
Source: ConclusionAuthors’ abstract
ABSTRACT
Objectives
To characterise osteoporosis medicine prescribing patterns following low‐trauma fractures and identify predictors of early treatment initiation.
Study Type
Retrospective population‐based cohort study.
Setting
New South Wales, Australia, using statewide linked administrative health data.
Participants
Adults aged ≥ 50 years with an incident low‐trauma fracture between January 2011 and June 2019.
Main Outcome Measures
Primary outcomes were osteoporosis treatment prescribing patterns and timing of initiation after incident fracture over 3 years, categorised as early (within 12 months), late (within 1 to 3 years) or no initiation. Secondary analyses examined predictors of time to treatment initiation within 12 months using Fine: Gray competing‐risk regression.
Results
Among 132,268 individuals with incident fractures, 63.7% (84,222) were female. Overall, 29,802 (22.5%) initiated osteoporosis medicine, whereas 102,466 (77.5%) remained untreated. Among females (mean [standard deviation] age, 77.7 [10.1] years), 20.1% initiated therapy within 12 months, 7.0% within 1 to 3 years, and 72.9% remained untreated. Among males (mean [standard deviation] age, 77.2 [10.0] years), the corresponding proportions were 10.8%, 3.7% and 85.6%. After accounting for the competing risk of death, treatment initiation was more likely with non‐distal fractures, older age, polypharmacy, prior steroid use, prior dual‐energy x‐ray absorptiometry and later fracture year, and less likely with greater comorbidity, rural or regional residence and prior hospitalisation for falls.
The strongest associations were for hip or vertebral fracture (subdistribution hazard ratio range, 1.90 to 3.03) and high comorbidity burden (subdistribution hazard ratio range, 0.72 to 0.75). Almost one in four late initiators had a refracture before starting treatment. Denosumab rapidly replaced oral bisphosphonates as the dominant therapy over time.
Conclusion
More than three‐quarters of individuals remain untreated after fracture, highlighting persistent and substantial gaps in secondary fracture prevention. Treatment initiation is strongly associated with fracture site and multimorbidity burden, and initiation rates are lower in males. Increasing reliance on denosumab underscores the need for careful long‐term treatment planning and strategies.
Plain Language Summary
The Known: After a fracture, the risk of another fracture is high. Osteoporosis medicines can help reduce this risk.
The New: In this large study of more than 132,000 people in New South Wales, Australia, with fractures, about one in four females and one in seven males started treatment with osteoporosis medicine within 3 years. Males and people with more health problems were less likely to receive treatment. Over time, denosumab replaced oral bisphosphonates as the most common therapy.
The Implications: There are major gaps in post‐fracture care, highlighting missed opportunities to prevent future fractures. Earlier treatment initiation should be a priority.
Publication and source details
Original title: Patterns of Osteoporosis Treatment Initiation Following Low‐Trauma Fracture: A Population‐Based Retrospective Cohort Study in New South Wales, Australia, Using Linked Administrative Health Data
Mike Lin; Huy Nguyen; Thach Tran; Robert D. Blank; Dana Bliuc; Jacqueline R. Center
The Medical Journal of Australia · 2026
* Correspondence:Mike Lin (m.lin@garvan.org.au)
© 2026 The Author(s). Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Medical Research Future Fund10.13039/501100025520 1137462 National Health and Medical Research Council10.13039/501100000925 1108886 Amgen Foundation, Competitive Bone Grant Prolia10.13039/100000042 BCGP‐06
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T21:46:19.629341+00:00
DOI: 10.5694/mja2.70285 · PMC13531723